Insider buys: On Nov 18, 2020, Director, Glenn P Muir, purchased 50,000 shares in G1 Therapeutics (GTHX) for $675,000.
It has a Market Cap of 544.056M
G1 Therapeutics is a a clinical-stage biopharmaceutical company which engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with...
Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions
GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September
FDA's move is a recognition that clinical data presented...